Atezolizumab ELISA (TECENTRIQ)

KRIBIOLISA™ Atezolizumab (TECENTRIQ) ELISA | KBI1027 | KRISHGEN BioSystems

The Atezolizumab (Tecentriq) ELISA kit is an assay intended for the quantitative determination of Atezolizumab (Tecentriq) in serum, plasma and cell culture samples. CE IVD marked.

Key features:

• uses highly specific monoclonal anti-idiotypic antibodies
• calibrators used is commerically available daratumumab injection itself 
• Recovery: 80-120%
• Precision CV <15%

This Atezolizumab ELISA is for determination of Atezolizumab in human serum, plasma and cell culture supernatant.

Assay Background:

Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against PD-L1. It is sold under the trade name Tecentriq. Atezolizumab inhibits interaction of PD-L1 with PD-1 and CD80 receptors. An Immune Check Point Inhibition, Atezolizumab triggers an anti-tumor response by preventing reduced activation of immune cells.

Assay Principle:

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Atezolizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Atezolizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti- Atezolizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Atezolizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.